Are we ready to downregulate mast cells?

Current Opinion in Immunology

Volumn 21, Issue 6, 2009, Pages 708-714

  Karra, Laila ^a   Berent Maoz, Beata ^a   Ben Zimra, Micha ^a   Levi Schaffer, Francesca ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD300 ANTIBODY; CD300A ANTIGEN; DEATH RECEPTOR; FAS ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN RECEPTOR; INHIBITORY RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD200; PROTEIN HGE2; SIGLEC 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ASTHMA; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; MAST CELL; NONHUMAN; PERITONITIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN ANAPHYLAXIS;

ANIMALS; ANTIGENS, CD; DOWN-REGULATION; HUMANS; MAST CELLS; RECEPTORS, DEATH DOMAIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 70449707323     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2009.09.010     Document Type: Review

References (74)

1. Padawer J. Mast cells: extended lifespan and lack of granule turnover under normal in vivo conditions. Exp Mol Pathol 20 (1974) 269-280
2. Levi-Schaffer F., and Shalit M. Proliferation and functional responses of bone marrow-derived mast cells after activation. Cell Immunol 148 (1993) 435-443
3. Levi-Schaffer F., Gare M., and Shalit M. Unresponsiveness of rat peritoneal mast cells to immunologic reactivation. J Immunol 145 (1990) 3418-3424
4. Royer B., Varadaradjalou S., Saas P., Gabiot A.C., Kantelip B., Feger F., Guillosson J.J., Kantelip J.P., and Arock M. Autocrine regulation of cord blood-derived human mast cell activation by IL-10. J Allergy Clin Immunol 108 (2001) 80-86
5. Nicholson D.W. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6 (1999) 1028-1042
6. Vaux D.L., and Korsmeyer S.J. Cell death in development. Cell 96 (1999) 245-254
7. Guicciardi M.E., and Gores G.J. Life and death by death receptors. FASEB J 23 (2009) 1625-1637
8. Mekori Y.A., Gilfillan A.M., Akin C., Hartmann K., and Metcalfe D.D. Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J Clin Immunol 21 (2001) 171-174
9. Mekori Y.A., Oh C.K., and Metcalfe D.D. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-Kit ligand. J Immunol 151 (1993) 3775-3784
10. Piliponsky A.M., and Levi-Schaffer F. Regulation of apoptosis in mast cells. Apoptosis 5 (2000) 435-441
11. Mahalingam D., Szegezdi E., Keane M., Jong S., and Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat Rev 35 (2009) 280-288
12. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
13. Yousefi S., and Simon H.U. SHP-1: a regulator of neutrophil apoptosis. Semin Immunol 15 (2003) 195-199
14. Robertson N.M., Zangrilli J.G., Steplewski A., Hastie A., Lindemeyer R.G., Planeta M.A., Smith M.K., Innocent N., Musani A., Pascual R., et al. Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival. J Immunol 169 (2002) 5986-5996
15. Daigle I., and Simon H.U. Alternative functions for TRAIL receptors in eosinophils and neutrophils. Swiss Med Wkly 131 (2001) 231-237
16. Butterfield J.H., Weiler D., Dewald G., and Gleich G.J. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 12 (1988) 345-355
17. Berent-Maoz B., Piliponsky A.M., Daigle I., Simon H.U., and Levi-Schaffer F. Human mast cells undergo TRAIL-induced apoptosis. J Immunol 176 (2006) 2272-2278. This work demonstrates that human mast cells express functional TRAIL death receptors whose action can be up-regulated by IgE-dependent activation. This is the first time that the function of death receptors is demonstrated on mast cells of human origin.
18. Berent-Maoz B., Salemi S., Mankuta D., Simon H.U., and Levi-Schaffer F. TRAIL mediated signaling in human mast cells: the influence of IgE-dependent activation. Allergy 63 (2008) 333-340. This is one of the few papers demonstrating the interplay between FcεRI and TRAIL and its effect on the expression of molecules involved in the apoptotic signal transduction in human mast cells.
19. Kashiwakura J., Yokoi H., Saito H., and Okayama Y. T cell proliferation by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells: comparison of gene expression profiles between human tonsillar and lung-cultured mast cells. J Immunol 173 (2004) 5247-5257
20. Alfredsson J., Puthalakath H., Martin H., Strasser A., and Nilsson G. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ 12 (2005) 136-144
21. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., and Peter M.E. Apoptosis signaling by death receptors. Eur J Biochem 254 (1998) 439-459
22. Hartmann K., Wagelie-Steffen A.L., von Stebut E., and Metcalfe D.D. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J Immunol 159 (1997) 4006-4014
23. Yoshikawa H., Nakajima Y., and Tasaka K. Enhanced expression of Fas-associated death domain-like IL-1-converting enzyme (FLICE)-inhibitory protein induces resistance to Fas-mediated apoptosis in activated mast cells. J Immunol 165 (2000) 6262-6269
24. Yeatman II C.F., Jacobs-Helber S.M., Mirmonsef P., Gillespie S.R., Bouton L.A., Collins H.A., Sawyer S.T., Shelburne C.P., and Ryan J.J. Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)-4 and IL-10 induces mouse mast cell apoptosis. J Exp Med 192 (2000) 1093-1103
25. Malbec O., and Daeron M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol Rev 217 (2007) 206-221
26. Katz H.R. Inhibition of pathologic inflammation by leukocyte Ig-like receptor B4 and related inhibitory receptors. Immunol Rev 217 (2007) 222-230
27. Katz H.R. Inhibitory receptors and allergy. Curr Opin Immunol 14 (2002) 698-704
28. Katz H.R. Inhibition of anaphylactic inflammation by the gp49B1 receptor on mast cells. Mol Immunol 38 (2002) 1301-1305
29. Chen C.C., Kong D.W., Cooper M.D., and Kubagawa H. Mast cell regulation via paired immunoglobulin-like receptor PIR-B. Immunol Res 26 (2002) 191-197
30. Abramson J., Xu R., and Pecht I. An unusual inhibitory receptor-the mast cell function-associated antigen (MAFA). Mol Immunol 38 (2002) 1307-1313
31. Kraft S., and Novak N. Fc receptors as determinants of allergic reactions. Trends Immunol 27 (2006) 88-95
32. Saxon A., Kepley C., and Zhang K. Accentuate the negative, eliminate the positive: engineering allergy therapeutics to block allergic reactivity through negative signaling. J Allergy Clin Immunol 121 (2008) 320-325
33. Daeron M., Jaeger S., Du Pasquier L., and Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 224 (2008) 11-43. This is an extensive in depth review of the ITIM-containing inhibitory receptors in major animal phyla from mammals to protozoa.
34. Cantoni C., Bottino C., Augugliaro R., Morelli L., Marcenaro E., Castriconi R., Vitale M., Pende D., Sivori S., Millo R., et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol 29 (1999) 3148-3159
35. Bachelet I., Munitz A., Moretta A., Moretta L., and Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 175 (2005) 7989-7995
36. Munitz A., Bachelet I., Eliashar R., Moretta A., Moretta L., and Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils. Blood 107 (2006) 1996-2003
37. Alvarez Y., Tang X., Coligan J.E., and Borrego F. The CD300a (IRp60) inhibitory receptor is rapidly upregulated on human neutrophils in response to inflammatory stimuli and modulates CD32a (FcgammaRIIa) mediated signaling. Mol Immunol 45 (2008) 253-258
38. Fong D.C., Malbec O., Arock M., Cambier J.C., Fridman W.H., and Daeron M. Selective in vivo recruitment of the phosphatidylinositol phosphatase SHIP by phosphorylated Fc gammaRIIB during negative regulation of IgE-dependent mouse mast cell activation. Immunol Lett 54 (1996) 83-91
39. Daeron M., Malbec O., Latour S., Arock M., and Fridman W.H. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest 95 (1995) 577-585
40. Lesourne R., Bruhns P., Fridman W.H., and Daeron M. Insufficient phosphorylation prevents Fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1. J Biol Chem 276 (2001) 6327-6336
41. Bachelet I., Munitz A., Berent-Maoz B., Mankuta D., and Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol 180 (2008) 6064-6069. This paper discusses the first bi-specific antibody linking c-Kit and CD300a. This paper demonstrates the inhibitory effects of the bispecific antibody on CBMC and HMC-1 cells and in mice in SCF-induced skin anaphylaxis.
42. Malbec O., Fridman W.H., and Daeron M. Negative regulation of c-Kit-mediated cell proliferation by Fc gamma RIIB. J Immunol 162 (1999) 4424-4429
43. Ju X., Zenke M., Hart D.N., and Clark G.J. CD300a/c regulate type I interferon and TNF-alpha secretion by human plasmacytoid dendritic cells stimulated with TLR7 and TLR9 ligands. Blood 112 (2008) 1184-1194
44. Kumagai H., Oki T., Tamitsu K., Feng S.Z., Ono M., Nakajima H., Bao Y.C., Kawakami Y., Nagayoshi K., Copeland N.G., et al. Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. Biochem Biophys Res Commun 307 (2003) 719-729
45. Bustamante C.D., Fledel-Alon A., Williamson S., Nielsen R., Hubisz M.T., Glanowski S., Tanenbaum D.M., White T.J., Sninsky J.J., Hernandez R.D., et al. Natural selection on protein-coding genes in the human genome. Nature 437 (2005) 1153-1157
46. Nielsen R., Bustamante C., Clark A.G., Glanowski S., Sackton T.B., Hubisz M.J., Fledel-Alon A., Tanenbaum D.M., Civello D., White T.J., et al. A scan for positively selected genes in the genomes of humans and chimpanzees. PLoS Biol 3 (2005) e170
47. Clark G.J., Ju X., Tate C., and Hart D.N. The CD300 family of molecules are evolutionarily significant regulators of leukocyte functions. Trends Immunol 30 (2009) 209-217. This is the first review to thouroughly discuss the CD300 family members and to summarize the current information regarding CD300 expression, distribution and their possible relevance to disease.
48. Speckman R.A., Wright Daw J.A., Helms C., Duan S., Cao L., Taillon-Miller P., Kwok P.Y., Menter A., and Bowcock A.M. Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet 112 (2003) 34-41
49. Cookson W.O., Ubhi B., Lawrence R., Abecasis G.R., Walley A.J., Cox H.E., Coleman R., Leaves N.I., Trembath R.C., Moffatt M.F., et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 27 (2001) 372-373
50. Barton A., Eyre S., Myerscough A., Brintnell B., Ward D., Ollier W.E., Lorentzen J.C., Klareskog L., Silman A., John S., et al. High resolution linkage and association mapping identifies a novel rheumatoid arthritis susceptibility locus homologous to one linked to two rat models of inflammatory arthritis. Hum Mol Genet 10 (2001) 1901-1906
51. Yokoi H., Myers A., Matsumoto K., Crocker P.R., Saito H., and Bochner B.S. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 61 (2006) 769-776
52. Floyd H., Ni J., Cornish A.L., Zeng Z., Liu D., Carter K.C., Steel J., and Crocker P.R. Siglec-8. A novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem 275 (2000) 861-866
53. Kikly K.K., Bochner B.S., Freeman S.D., Tan K.B., Gallagher K.T., D'Alessio K.J., Holmes S.D., Abrahamson J.A., Erickson-Miller C.L., Murdock P.R., et al. Identification of SAF-2, a novel Siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol 105 (2000) 1093-1100
54. Nutku E., Aizawa H., Hudson S.A., and Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 101 (2003) 5014-5020
55. Crocker P.R., Paulson J.C., and Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 7 (2007) 255-266
56. Bochner B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy 39 (2009) 317-324
57. Yokoi H., Choi O.H., Hubbard W., Lee H.S., Canning B.J., Lee H.H., Ryu S.D., von Gunten S., Bickel C.A., Hudson S.A., et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol 121 (2008) 499-505 e491. This paper shows that unlike other members of the siglec family, siglec-8 does not lead to apoptosis in mast cells, but to inhibition of IgE-mediated activation. While other papers have demonstrated siglec-8 function mostly on eosinophils, this is the first paper to do so on mast cells.
58. Tateno H., Crocker P.R., and Paulson J.C. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 15 (2005) 1125-1135
59. Ishida A., Ohta M., Toda M., Murata T., Usui T., Akita K., Inoue M., and Nakada H. Mucin-induced apoptosis of monocyte-derived dendritic cells during maturation. Proteomics 8 (2008) 3342-3349. This is the first suggestion of a potential ligand for the human and murine siglec-8 and Siglec-F.
60. Ghannadan M., Hauswirth A.W., Schernthaner G.H., Muller M.R., Klepetko W., Schatzl G., Sperr W.R., Buhring H.J., and Valent P. Detection of novel CD antigens on the surface of human mast cells and basophils. Int Arch Allergy Immunol 127 (2002) 299-307
61. Lienard H., Bruhns P., Malbec O., Fridman W.H., and Daeron M. Signal regulatory proteins negatively regulate immunoreceptor-dependent cell activation. J Biol Chem 274 (1999) 32493-32499
62. Meyaard L., van der Vuurst de Vries A.R., de Ruiter T., Lanier L.L., Phillips J.H., and Clevers H. The epithelial cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyte-associated immunoglobulin-like receptor (LAIR). J Exp Med 194 (2001) 107-112
63. Lebbink R.J., de Ruiter T., Adelmeijer J., Brenkman A.B., van Helvoort J.M., Koch M., Farndale R.W., Lisman T., Sonnenberg A., Lenting P.J., et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med 203 (2006) 1419-1425
64. Zhang S., and Phillips J.H. Identification of tyrosine residues crucial for CD200R-mediated inhibition of mast cell activation. J Leukoc Biol 79 (2006) 363-368
65. Cherwinski H.M., Murphy C.A., Joyce B.L., Bigler M.E., Song Y.S., Zurawski S.M., Moshrefi M.M., Gorman D.M., Miller K.L., Zhang S., et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 174 (2005) 1348-1356
66. Zhang S., Cherwinski H., Sedgwick J.D., and Phillips J.H. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173 (2004) 6786-6793
67. Minas K., and Liversidge J. Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal?. Crit Rev Immunol 26 (2006) 213-230
68. Tam S.W., Demissie S., Thomas D., and Daeron M. A bispecific antibody against human IgE and human FcgammaRII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy 59 (2004) 772-780
69. Zhu D., Kepley C.L., Zhang M., Zhang K., and Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med 8 (2002) 518-521
70. Zhang K., Kepley C.L., Terada T., Zhu D., Perez H., and Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 114 (2004) 321-327
71. Mertsching E., Bafetti L., Hess H., Perper S., Giza K., Allen L.C., Negrou E., Hathaway K., Hopp J., Chung J., et al. A mouse Fcgamma-Fcepsilon protein that inhibits mast cells through activation of FcgammaRIIB, SH2 domain-containing inositol phosphatase 1, and SH2 domain-containing protein tyrosine phosphatases. J Allergy Clin Immunol 121 (2008) 441-447 e445
72. Bachelet I., Munitz A., and Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 117 (2006) 1314-1320
73. Munitz A., Bachelet I., and Levi-Schaffer F. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. J Allergy Clin Immunol 118 (2006) 1082-1089
74. Herrmann T., Grosse-Hovest L., Otz T., Krammer P.H., Rammensee H.G., and Jung G. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 68 (2008) 1221-1227